항Hu 및 항SOX1자가항체가 동시에 확인된 아테졸리주맙 연관 자가면역뇌염
Coexistence of Anti-Hu and Anti-SOX1 Autoantibodies in Atezolizumab-related Encephalitis
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Although immune checkpoint inhibitor-related encephalitis has been reported, its underlying mechanism and treatment strategies remain unclear. Here, we present the case of a 60-yearold male patient with small cell lung cancer who developed autoimmune encephalitis during treatment with atezolizumab. Notably, this case involved the concurrent detection of two paraneoplastic autoantibodies (anti-Hu and anti-SOX1). Encephalitis was treated by discontinuing atezolizumab and administering steroids, despite the persistence of the antibodies. This case provides insights into the interaction between immune checkpoint inhibitors and paraneoplastic autoantibodies.
Abstract
Although immune checkpoint inhibitor-related encephalitis has been reported, its underlying mechanism and treatment strategies remain unclear. Here, we present the case of a 60-yearold male patient with small cell lung cancer who developed autoimmune encephalitis during treatment with atezolizumab. Notably, this case involved the concurrent detection of two paraneoplastic autoantibodies (anti-Hu and anti-SOX1). Encephalitis was treated by discontinuing atezolizumab and administering steroids, despite the persistence of the antibodies. This case provides insights into the interaction between immune checkpoint inhibitors and paraneoplastic autoantibodies.
참고문헌 (12)
- Darvin P, "Immune checkpoint inhibitors : recent progress and potential biomarkers", Exp Mol Med, 50, pp.1~11 (2018)
- Socinski MA, "Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC", N Engl J Med, 378, pp.2288~2301 (2018)
- Velasco R, "Encephalitis induced by immune checkpoint inhibitors : a sys-Tematic review", JAMA Neurol, 78, pp.864~873 (2021)
- Bien CG, "Immunopathology of autoantibody-associated encephalitides : clues for pathogenesis", Brain, 135, pp.1622~1638 (2012)
- Farina A, "Anti-Hu antibodies in patients with neurologic side effects of immune checkpoint inhibitors", Neurol Neuroimmunol Neuroinflammation, 10, pp.e200058~ (2022)
- Vogrig A, "Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors", Neurol Neuroimmunol Neuroinflammation, 6, pp.e604~ (2019)
- Graus F, "A clinical approach to diagnosis of autoimmune encephalitis", Lancet Neurol, 15, pp.391~404 (2016)
- Sun X, "Anti-SOX1 antibodies in paraneoplastic neurological syndrome", J Clin Neurol, 16, pp.530~546 (2020)
- Qiao S, "Coexistence of multiple anti-neuronal antibodies in autoimmune encephalitis in China : a multi-center study", Front Immunol, 13, pp.858766~ (2022)
- Albarrán V, "Neurologic toxicity of immune checkpoint inhibitors : a review of literature", Front Pharmacol, 13, pp.774170~ (2022)
- Özdirik B, "Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma : case report and literature review", Medicine(Baltimore), 100, pp.e26377~ (2021)
- Nersesjan V, "Autoimmune encephalitis related to cancer treatment with immune checkpoint inhibitors : a systematic review", Neurology, 97, pp.e191~e202 (2021)